Fenofibrate NDC 69315-290

NDC codes

FDA NDC Directory

Product NDC (as listed)69315-290Labeler and product segments. Claims need a package NDC.

Product NDC at billing width69315-0290Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
69315-290-05	69315029005	500 TABLET, FILM COATED in 1 BOTTLE (69315-290-05)Marketed from Aug 20, 2022
69315-290-09	69315029009	90 TABLET, FILM COATED in 1 BOTTLE (69315-290-09)Marketed from Aug 20, 2022

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Fenofibrate
Generic name (nonproprietary): fenofibrate
Active ingredients: Fenofibrate — 160 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: Leading Pharma, LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 210606
Marketing start: Aug 20, 2022
Listing expires: Dec 31, 2026
Identifiers: Product ID 69315-290_34d57f15-8d57-4357-b7fe-e2ffb840359cSPL ID 34d57f15-8d57-4357-b7fe-e2ffb840359cSPL set ID f73a40ef-1513-4a07-a5a9-51efb30bf560RxCUI 349287, 351133UNII U202363UOSUPC 0369315290057
Pharmacologic class: Peroxisome Proliferator Receptor alpha Agonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N469315029005 followed by a unit qualifier and the quantity

Package 69315-0290-05. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Dec 6, 2024.

Indications (excerpt from the label)

Fenofibrate is a peroxisome proliferator-activated receptor (PPAR) alpha agonist indicated as an adjunct to diet: To reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia ( 1.1 ). For treatment of adult patients with severe hypertriglyceridemia ( 1.2 ). Limitations of Use: Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus ( 5.1 ). 1.1 Primary Hypercholesterolemia or Mixed Dyslipidemia Fenofibrate tablets are indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (To…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 210606

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 210606
Product	Strength	Form · route	Labeler	Product NDC
Fenofibrate	Fenofibrate 54 mg/1	Tablet, Film coatedOral	Leading Pharma, LLC	69315-289
Fenofibrate	Fenofibrate 54 mg/1	Tablet, Film coatedOral	Laurus Labs Limited	42385-935
Fenofibrate	Fenofibrate 160 mg/1	Tablet, Film coatedOral	Laurus Labs Limited	42385-936